

Supplementary Data

SUPPLEMENTARY TABLE S1. STUDY VIROLOGICAL OUTCOMES, BY ACCESS TO LOCAL VIRAL LOAD AMONG PATIENT PARTICIPATING TO THE PAN-AFRICAN STUDIES TO EVALUATE RESISTANCE COHORT 2007–2015

		<i>Full access to VL</i>		<i>Access to VL phasing in</i>		<i>No access to VL</i>	
		<i>Switch</i>	<i>Same regimen</i>	<i>Switch</i>	<i>Same regimen</i>	<i>Switch</i>	<i>Same regimen</i>
Virological status during follow-up visit for 2,420 patients with ≥ 2 VL results	Confirmed virological failure: at least two consecutive sVL $\geq 1,000$ cps/mL ($N=266$)	61 (37%)	105 (63%)	16 (25%)	48 (75%)	14 (39%)	22 (61%)
	One isolated sVL $\geq 1,000$ cps/mL ($N=159$)	23 (24%)	74 (76%)	2 (4%)	44 (96%)	1 (6%)	15 (94%)
	Continuous virological suppression: all VL $<1,000$ cps/mL ($N=1995$)	13 (1%)	1,130 (99%)	12 (2%)	518 (98%)	7 (2%)	315 (98%)
Virological status at EoP for 2,420 patients with ≥ 2 VL results	Confirmed virological failure two consecutive sVL $\geq 1,000$ cpm at EoP. ($N=137$)	3 (4%)	77 (96%)	0 (0%)	41 (100%)	0 (0%)	16 (100%)
	Single sVL $\geq 1,000$ cpm at EoP ($N=123$)	15 (22%)	53 (78%)	3 (8%)	36 (92%)	2 (13%)	14 (88%)
	Virological suppression at EoP sVL $<1,000$ cpm $N=2,095$	47 (4%)	1,179 (96%)	10 (2%)	533 (98%)	4 (1%)	322 (99%)
	No additional VL after switch at EoP ($N=65$)	32	na	17	0	16	0

EoP, end of program; sVL, study plasma viral load; VL, viral load.